Emmanuel Broussolle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2591316/publications.pdf

Version: 2024-02-01

107 papers	6,873 citations	87401 40 h-index	71088 80 g-index
111 all docs	111 docs citations	111 times ranked	8329 citing authors

#	Article	IF	Citations
1	Fatigue in de novo Parkinsonâ€™s Disease: Expanding the Neuropsychiatric Triad?. Journal of Parkinson's Disease, 2022, 12, 1329-1337.	1.5	5
2	Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease. Movement Disorders, 2022, 37, 1211-1221.	2.2	14
3	Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs. Movement Disorders, 2021, 36, 2888-2900.	2.2	37
4	Characterization of Recessive Parkinson Disease in a Large Multicenter Study. Annals of Neurology, 2020, 88, 843-850.	2.8	40
5	Liver transplantation as a rescue therapy for severe neurologic forms of Wilson disease. Neurology, 2020, 94, e2189-e2202.	1.5	36
6	Early limbic microstructural alterations in apathy and depression in de novo Parkinson's disease. Movement Disorders, 2019, 34, 1644-1654.	2.2	52
7	What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective. Parkinsonism and Related Disorders, 2019, 59, 93-100.	1.1	29
8	Clonidine modulates the activity of the subthalamicâ€supplementary motor loop: evidence from a pharmacological study combining deep brain stimulation and electroencephalography recordings in Parkinsonian patients. Journal of Neurochemistry, 2018, 146, 333-347.	2.1	14
9	Subthalamic stimulation and neuropsychiatric symptoms in Parkinsonâ€™s disease: results from a long-term follow-up cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 836-843.	0.9	52
10	Historical crossroads in the conceptual delineation of apathy in Parkinsonâ€™s disease. Brain, 2018, 141, 613-619.	3.7	8
11	Screening of Wilsonâ€™s disease in a psychiatric population: difficulties and pitfalls. A preliminary study. Annals of General Psychiatry, 2017, 16, 19.	1.2	22
12	Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinsonâ€™s Disease: Implication for Treatment. Current Neurology and Neuroscience Reports, 2017, 17, 76.	2.0	79
13	Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease. Movement Disorders, 2017, 32, 1566-1573.	2.2	61
14	Personality, dopamine, and Parkinson's disease: Insights from subthalamic stimulation. Movement Disorders, 2017, 32, 1191-1200.	2.2	28
15	Liver Transplantation in Wilson's Disease with Neurological Impairment: Evaluation in 4 Patients. European Neurology, 2017, 77, 5-15.	0.6	23
16	Social cognition in Wilsonâ€™s disease: A new phenotype?. PLoS ONE, 2017, 12, e0173467.	1.1	12
17	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Movement Disorders, 2016, 31, 1049-1054.	2.2	28
18	Slowness in Movement Initiation is Associated with Proactive Inhibitory Network Dysfunction in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2016, 6, 433-440.	1.5	20

#	Article	IF	Citations
19	Longitudinal Executive Changes in Drivers with Parkinson's Disease: Study Using Neuropsychological and Driving Simulator Tasks. European Neurology, 2016, 76, 143-150.	0.6	9
20	The prominent role of serotonergic degeneration in apathy, anxiety and depression inde novoParkinsonâ€™s disease. Brain, 2016, 139, 2486-2502.	3.7	188
21	Distinct effects of dopamine vs STN stimulation therapies in associative learning and retention in Parkinson disease. Behavioural Brain Research, 2016, 302, 131-141.	1.2	6
22	Imaging Dopamine and Serotonin Systems on MPTP Monkeys: A Longitudinal PET Investigation of Compensatory Mechanisms. Journal of Neuroscience, 2016, 36, 1577-1589.	1.7	42
23	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. American Journal of Human Genetics, 2016, 98, 500-513.	2.6	333
24	Postoperative apathy can neutralise benefits in quality of life after subthalamic stimulation for Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 311-318.	0.9	49
25	Interaction of Noradrenergic Pharmacological Manipulation and Subthalamic Stimulation on Movement Initiation Control in Parkinson's Disease. Brain Stimulation, 2015, 8, 27-35.	0.7	22
26	Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate. Brain, 2015, 138, 2632-2647.	3.7	54
27	Dopa-Responsive Dystonia and gait analysis: A case study of levodopa therapeutic effects. Brain and Development, 2015, 37, 643-650.	0.6	8
28	Imagerie cÃ©rÃ©brale. , 2015, , 133-142.e3.		0
29	History of Physical and Â‘Moral' Treatment of Hysteria. Frontiers of Neurology and Neuroscience, 2014, 35, 181-197.	3.0	15
30	Dissociable dorsal and ventral frontostriatal working memory circuits: Evidence from subthalamic stimulation in Parkinson's disease. Human Brain Mapping, 2014, 35, 552-566.	1.9	13
31	Augusta Dejerine-Klumpke (1859-1927): An Extraordinary Neurologist and an Inspiration for All Women in Medical Careers. Pediatric Neurology, 2014, 50, 547-548.	1.0	9
32	Heterogeneity and frequency of movement disorders in juvenile and adult-onset Niemann-Pick C disease. Journal of Neurology, 2014, 261, 174-179.	1.8	43
33	Motor cortex stimulation does not improve dystonia secondary to a focal basal ganglia lesion. Neurology, 2014, 82, 156-162.	1.5	4
34	Relapse of tardive dystonia after globus pallidus deep-brain stimulation discontinuation. Journal of Neurology, 2014, 261, 1636-1637.	1.8	12
35	Deep-brain stimulation for dystonia: current indications and future orientations. Future Neurology, 2014, 9, 77-87.	0.9	1
36	Effectiveness of Anti-Psychotics and Related Drugs in the Huntington French-Speaking Group Cohort. PLoS ONE, 2014, 9, e85430.	1.1	17

#	Article	IF	Citations
37	Deep Brain Stimulation of the Subthalamic Nucleus, but not Dopaminergic Medication, Improves Proactive Inhibitory Control of Movement Initiation in Parkinson's Disease. Neurotherapeutics, 2013, 10, 154-167.	2.1	38
38	Psychostimulant effect of levodopa: reversing sensitisation is possible. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 18-22.	0.9	36
39	C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain, 2013, 136, 385-391.	3.7	143
40	A Common Optimization Principle for Motor Execution in Healthy Subjects and Parkinsonian Patients. Journal of Neuroscience, 2013, 33, 665-677.	1.7	64
41	Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain, 2013, 136, 1568-1577.	3.7	215
42	Absence of Airway Secretion Accumulation Predicts Tolerance of Noninvasive Ventilation in Subjects With Amyotrophic Lateral Sclerosis. Respiratory Care, 2013, 58, 1424-1432.	0.8	37
43	Impact of specific executive functions on driving performance in people with Parkinson's disease. Movement Disorders, 2013, 28, 1941-1948.	2.2	32
44	A Functional Magnetic Resonance Imaging Study of Pathophysiological Changes Responsible for Mirror Movements in Parkinsonâ€™s Disease. PLoS ONE, 2013, 8, e66910.	1.1	18
45	Rapid Presentation of Emotional Expressions Reveals New Emotional Impairments in Touretteâ€™s Syndrome. Frontiers in Human Neuroscience, 2013, 7, 149.	1.0	9
46	Subthalamic stimulation in Parkinsonâ€™s disease: restoring the balance of motivated behaviours. Brain, 2012, 135, 1463-1477.	3.7	275
47	PET functional imaging of deep brain stimulation in Parkinsonâ€™s disease. Journal of Neurolinguistics, 2012, 25, 133-138.	0.5	2
48	Functional imaging of non-motor signs in Parkinson's disease. Journal of the Neurological Sciences, 2012, 315, 9-14.	0.3	9
49	Relationships between Cognitive Functions and Driving Behavior in Parkinsonâ€™s Disease. European Neurology, 2012, 68, 98-107.	0.6	31
50	Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Movement Disorders, 2012, 27, 84-89.	2.2	112
51	G303V tau mutation presenting with progressive supranuclear palsyâ€“like features. Movement Disorders, 2012, 27, 581-583.	2.2	14
52	Advanced Parkinson's disease effect on goal-directed and habitual processes involved in visuomotor associative learning. Frontiers in Human Neuroscience, 2012, 6, 351.	1.0	22
53	Subthalamic nucleus stimulation selectively improves motor and visual memory performance in Parkinson's disease. Movement Disorders, 2011, 26, 2019-2025.	2.2	15
54	Impaired updating ability in drivers with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 218-223.	0.9	47

#	Article	IF	Citations
55	Contact dependent reproducible hypomania induced by deep brain stimulation in Parkinson's disease: clinical, anatomical and functional imaging study. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 607-614.	0.9	89
56	A Major Determinant for Binding and Aminoacylation of tRNAAla in Cytoplasmic Alanyl-tRNA Synthetase Is Mutated in Dominant Axonal Charcot-Marie-Tooth Disease. American Journal of Human Genetics, 2010, 86, 77-82.	2.6	194
57	Achille Alexandre Souques (1860â€“1944). Journal of Neurology, 2010, 257, 1047-1048.	1.8	7
58	Do the effects measured by intraoperative and postoperative STN macrostimulation in Parkinsonâ€™s disease match?. Journal of Neurology, 2010, 257, 1453-1456.	1.8	6
59	Table tennis dystonia. Movement Disorders, 2010, 25, 394-397.	2.2	27
60	Phenotypic Variability of Episodic Ataxia Type 2 Mutations: A Family Study. European Neurology, 2010, 64, 114-116.	0.6	23
61	Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain, 2010, 133, 1111-1127.	3.7	453
62	Neurology Outside Paris following Charcot. Frontiers of Neurology and Neuroscience, 2010, 29, 170-186.	3.0	4
63	Cerebrospinal fluid detection of enterovirus genome in ALS: A study of 242 patients and 354 controls. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 277-282.	2.3	27
64	Neuroendocrine Disturbances in Huntington's Disease. PLoS ONE, 2009, 4, e4962.	1.1	103
65	A Multitracer Dopaminergic PET Study of Young-Onset Parkinsonian Patients With and Without Parkin Gene Mutations. Journal of Nuclear Medicine, 2009, 50, 1244-1250.	2.8	37
66	Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurology, The, 2009, 8, 709-717.	4.9	313
67	Bilateral subthalamic nucleus stimulation in advanced Parkinsonâ€™s disease: Five year follow-up. Journal of Neurology, 2009, 256, 225-233.	1.8	155
68	Jules Froment (1878â€“1946). Journal of Neurology, 2009, 256, 1581-1582.	1.8	3
69	PET Functional Imaging of Deep Brain Stimulation in Movement Disorders and Psychiatry. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1743-1754.	2.4	45
70	Globus Pallidus Stimulation Reduces Frontal Hyperactivity in Tardive Dystonia. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1127-1138.	2.4	47
71	Word processing in Parkinson's disease is impaired for action verbs but not for concrete nouns. Neuropsychologia, 2008, 46, 743-756.	0.7	247
72	The ability to assess muscular force in asymmetrical Parkinson's disease. Cortex, 2008, 44, 82-89.	1.1	20

#	Article	IF	Citations
73	LRRK2emph Exon 41 Mutations in Sporadic Parkinson Disease in Europeans. Archives of Neurology, 2007, 64, 425.	4.9	51
74	Functional anatomy of motor urgency. NeuroImage, 2007, 37, 243-252.	2.1	29
75	Evidence for progressive changes in clinical presentation of myoclonus-dystonia. Movement Disorders, 2007, 22, 1516-1517.	2.2	11
76	Contribution of Jules Froment to the study of Parkinsonian rigidity. Movement Disorders, 2007, 22, 909-914.	2.2	48
77	Bilateral subthalamic nucleus stimulation in advanced Parkinsonâ€™s disease. Journal of Neurology, 2007, 254, 99-106.	1.8	35
78	Hereditary hemochromatosis and movement disorders: the still controversial relationship. Journal of Neurology, 2006, 253, 261-262.	1.8	3
79	â€œParadoxical Kinesisâ€•is not a Hallmark of Parkinson's disease but a general property of the motor system. Movement Disorders, 2006, 21, 1490-1495.	2.2	74
80	Chorea induced by globus pallidus externus stimulation in a dystonic patient. Movement Disorders, 2006, 21, 1771-1773.	2.2	15
81	Spinocerebellar ataxia with sensory neuropathy (SCA25). Cerebellum, 2005, 4, 58-61.	1.4	18
82	Can chronic subthalamic nucleus stimulation induce de novo tremor in Parkinson's disease?. Movement Disorders, 2005, 20, 1066-1069.	2.2	3
83	Striatal dopamine during sensorial stimulations: A [18F]FDOPA PET study in human and cats. Neuroscience Letters, 2005, 383, 63-67.	1.0	2
84	Spinocerebellar ataxia with sensory neuropathy (SCA25) maps to chromosome 2p. Annals of Neurology, 2004, 55, 97-104.	2.8	78
85	Adrafinil-induced orofacial dyskinesia. Movement Disorders, 2004, 19, 965-966.	2.2	9
86	Globus pallidus internus stimulation in primary generalized dystonia: a H215O PET study. Brain, 2004, 127, 1899-1908.	3.7	94
87	Subthalamic nucleus stimulation and dysarthria in Parkinsonâ€™s disease: a PET study. Brain, 2004, 127, 602-615.	3.7	99
88	Effect of sensory stimulus on striatal dopamine release in humans and cats: a [11C]raclopride PET study. Neuroscience Letters, 2004, 368, 46-51.	1.0	6
89	Role of Dopaminergic Treatment in Dopamine Receptor Down-regulation in Advanced Parkinson Disease. Archives of Neurology, 2004, 61, 1705.	4.9	74
90	Atypical propriospinal myoclonus with possible relationship to ? interferon therapy. Movement Disorders, 2003, 18, 1564-1568.	2.2	40

#	Article	IF	Citations
91	How much phenotypic variation can be attributed toparkingenotype?. Annals of Neurology, 2003, 54, 176-185.	2.8	271
92	Evidence for Deficiencies in Perceptual and Semantic Olfactory Processes in Parkinson's Disease. Chemical Senses, 2003, 28, 537-543.	1.1	34
93	Young-Onset Parkinson Disease With and Without Parkin Gene Mutations. Archives of Neurology, 2003, 60, 713.	4.9	35
94	Dissociable processing of temporal structure in repetitive eyeâ€“hand movements in Parkinsonâ€™s disease. Neuropsychologia, 2002, 40, 1407-1418.	0.7	10
95	Orofacial dyskinesias in a patient with primary biliary cirrhosis: A clinicopathological case report and review. Movement Disorders, 2002, 17, 415-419.	2.2	18
96	Effects of subthalamic nucleus stimulation on actual and imagined movement in Parkinson's disease : a PET study. Journal of Neurology, 2002, 249, 1689-1698.	1.8	64
97	Tactile hallucinations in Parkinson's disease. Journal of Neurology, 2002, 249, 1699-1703.	1.8	82
98	CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td (leukoe Journal of Cutaneous Pathology, 2002, 29, 498-501.	0.7	11
99	A Wide Variety of Mutations in the Parkin Gene Are Responsible for Autosomal Recessive Parkinsonism in Europe. Human Molecular Genetics, 1999, 8, 567-574.	1.4	571
100	Phosphorus and proton magnetic resonance spectroscopy in episodic ataxia type 2. Annals of Neurology, 1999, 46, 256-259.	2.8	49
101	Chromosome 6â€“Linked Autosomal Recessive Early-Onset Parkinsonism: Linkage in European and Algerian Families, Extension of the Clinical Spectrum, and Evidence of a Small Homozygous Deletion in One Family. American Journal of Human Genetics, 1998, 63, 88-94.	2.6	83
102	Slowly progressive anarthria with late anterior opercular syndrome: a variant form of frontal cortical atrophy syndromes. Journal of the Neurological Sciences, 1996, 144, 44-58.	0.3	117
103	Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Movement Disorders, 1995, 10, 672-674.	2.2	257
104	Motor imagery of a lateralized sequential task is asymmetrically slowed in hemi-Parkinson's patients. Neuropsychologia, 1995, 33, 727-741.	0.7	214
105	P.O.E.M.S. syndrome with complete recovery after treatment of a solitary plasmocytoma. Clinical Neurology and Neurosurgery, 1991, 93, 165-170.	0.6	21
106	Effects of Substance Abuse on Ventricular and Sulcal Measures Assessed by Computerised Tomography. British Journal of Psychiatry, 1991, 159, 217-221.	1.7	26
107	RU 24722, a new eburnamine derivative, induces selective alterations in cerebral glucose utilization in freely moving rat. European Journal of Pharmacology, 1989, 159, 225-231.	1.7	6